Last Updated on December 4, 2021 by The Health Master
The National Pharmaceutical Pricing Authority (NPPA) is planning to hire a set of consultants and young professionals skilled in specific courses to engage them in various levels of its operations on a contract basis.
It has called for applications from eligible candidates to fill the posts of 21 consultants and 12 young professionals, within 21 days of the publication of the circular, which was issued on November 30, 2021.
The posts notified as under:
- A Consultant (non-tech, Grade II) with three years experience as under secretary or deputy secretary or equivalent in Public Sector Undertaking or local body under the age of 64 years on the last date of the application.
- A Senior consultant (legal),
- 2 posts of senior consultant (pharma),
- 2 posts of consultant (legal)
- 4 posts of consultant (pharma),
- 2 posts of consultant (medical device),
- 7 posts of consultant (cost),
- 2 posts of consultant (data analysis),
- 12 posts of young professionals (data analysis, medical device and pharma)
- 4 posts of young professionals (data analysis),
- 6 posts of young professional (pharma),
- 2 posts of young professionals (medical device).
Candidates will be hired on a contractual basis for a period of one year, which can be extended up to 3 years depending on the satisfactory performance of the candidate or the needs of NPPA.
Senior consultants will be paid a fixed amount of Rs. 60,000 per month, consultants Rs. 50,000 a month and consultant (non-tech, Grade II) at Rs. 65,000 per month as consultancy fees.
The young professionals will get a fixed consultancy fee of Rs, 40,000 a month. The consolidated fee will include applicable taxes and no other allowance will be paid.
For retired government servants appointed as consultants, the consultancy fee shall be decided as per the relevant rules of Government of India subject to the ceiling, it added.
The decision comes at a time when the drug price controller is gearing up to meet the requirements of a fast growing pharma and medical devices sector.
The price regulator is expecting to see more responsibilities falling on its shoulders with new formulations, delivery methods and others are emerging.
In the wake of the C-19 pandemic and the peculiar situation it has created, the NPPA has seen a responsibility to tightly monitor the market and ensure that essential drugs are available on the market and accessible to everybody at a reasonable price, while also ensuring that there are no exorbitant price increases for these drugs due to heightened demand.
It has also used the trade margin rationalisation tool to control the prices of essential medical devices such as blood pressure monitor, pulse oximeter, glucometer and others, during the pandemic period.
For informative videos by The Health Master, click on the below YouTube icon: